Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results

#341

Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.

Aim(s): To evaluate the effect of EVE in pNET patients with elevated v. non-elevated CgA and NSE, and their association with PFS in a randomized trial.

Materials and methods: In RADIANT-3 (EVE 10mg/d [n=207] v. PB [n=203]), serum CgA and NSE were measured at baseline and monthly thereafter if > upper limit of normal (ULN). Patients were categorized by CgA and NSE level (elevated or non-elevated). Cut-off values for elevated baseline were 2×ULN CgA (eCgA, 72.8ng/mL) and >ULN NSE (eNSE, 8.6ng/mL).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Oberg K, Anthony L, Sideris L, Chen L, Cherfi A,

Keywords: mTOR, everolimus, chromogranin A, neuron-specific enolase, pancreatic neuroendocrine tumors,